Literature DB >> 20739907

A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background.

Montserrat García-Closas1, David W Hein, Debra Silverman, Núria Malats, Meredith Yeager, Kevin Jacobs, Mark A Doll, Jonine D Figueroa, Dalsu Baris, Molly Schwenn, Manolis Kogevinas, Alison Johnson, Nilanjan Chatterjee, Lee E Moore, Timothy Moeller, Francisco X Real, Stephen Chanock, Nathaniel Rothman.   

Abstract

The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We reported earlier on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on seven single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3' end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype. The agreement between the 7-SNP NAT2 inferred phenotype and the tag SNP, rs1495741, was initially assessed in 2174 individuals from the Spanish Bladder Cancer Study (SBCS), and confirmed in a subset of individuals from the Main and Vermont component the New England Bladder Cancer Study (NEBCS). We also investigated the association of rs1495741 genotypes with NAT2 catalytic activity in cryopreserved hepatocytes from 154 individuals of European background. We observed very strong agreement between rs1495741 and the 7-SNP inferred NAT2 phenotype: sensitivity and specificity for the NAT2 slow phenotype was 99 and 95%, respectively. Our findings were replicated in an independent population from the NEBCS. Estimates for the association between NAT2 slow phenotype and bladder cancer risk in the SBCS and its interaction with cigarette smoking were comparable for the 7-SNP inferred NAT2 phenotype and rs1495741. In addition, rs1495741 genotypes were strongly related to NAT2 activity measured in hepatocytes (P<0.0001). A novel NAT2 tag SNP (rs1495741) predicts with high accuracy the 7-SNP inferred NAT2 phenotype, and thus can be used as a sole marker in pharmacogenetic or epidemiological studies of populations of European background. These findings illustrate the utility of tag SNPs, often used in genome-wide association studies (GWAS), to identify novel phenotypic markers. Further studies are required to determine the functional implications of rs1495741 and the structure and evolution of the haplotype on which it resides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20739907      PMCID: PMC3003749          DOI: 10.1097/FPC.0b013e32833e1b54

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  18 in total

Review 1.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.

Authors:  D W Hein; M A Doll; A J Fretland; M A Leff; S J Webb; G H Xiao; U S Devanaboyina; N A Nangju; Y Feng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

2.  Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes.

Authors:  M A Doll; D W Hein
Journal:  Anal Biochem       Date:  2001-01-01       Impact factor: 3.365

3.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.

Authors:  H B HUGHES; J P BIEHL; A P JONES; L H SCHMIDT
Journal:  Am Rev Tuberc       Date:  1954-08

4.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

Authors:  Montserrat García-Closas; Núria Malats; Debra Silverman; Mustafa Dosemeci; Manolis Kogevinas; David W Hein; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Gemma Castaño-Vinyals; Meredith Yeager; Robert Welch; Stephen Chanock; Nilanjan Chatterjee; Sholom Wacholder; Claudine Samanic; Montserrat Torà; Francisco Fernández; Francisco X Real; Nathaniel Rothman
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

Review 5.  Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned.

Authors:  Nathaniel Rothman; Montserrat Garcia-Closas; David W Hein
Journal:  Int J Epidemiol       Date:  2007-02       Impact factor: 7.196

6.  A case-control study of smoking and bladder cancer risk: emergent patterns over time.

Authors:  Dalsu Baris; Margaret R Karagas; Castine Verrill; Alison Johnson; Angeline S Andrew; Carmen J Marsit; Molly Schwenn; Joanne S Colt; Sai Cherala; Claudine Samanic; Richard Waddell; Kenneth P Cantor; Alan Schned; Nathaniel Rothman; Jay Lubin; Joseph F Fraumeni; Robert N Hoover; Karl T Kelsey; Debra T Silverman
Journal:  J Natl Cancer Inst       Date:  2009-11-16       Impact factor: 13.506

7.  Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer.

Authors:  Anne C Deitz; Nathanial Rothman; Timothy R Rebbeck; Richard B Hayes; Wong-Ho Chow; Wei Zheng; David W Hein; Montserrat García-Closas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-09       Impact factor: 4.254

Review 8.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 9.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

10.  A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

Authors:  Nathaniel Rothman; Montserrat Garcia-Closas; Nilanjan Chatterjee; Nuria Malats; Xifeng Wu; Jonine D Figueroa; Francisco X Real; David Van Den Berg; Giuseppe Matullo; Dalsu Baris; Michael Thun; Lambertus A Kiemeney; Paolo Vineis; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Thorunn Rafnar; Michelle A T Hildebrandt; Anne E Kiltie; Olivier Cussenot; Klaus Golka; Rajiv Kumar; Jack A Taylor; Jose I Mayordomo; Kevin B Jacobs; Manolis Kogevinas; Amy Hutchinson; Zhaoming Wang; Yi-Ping Fu; Ludmila Prokunina-Olsson; Laurie Burdett; Meredith Yeager; William Wheeler; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Stephanie J Weinstein; Jarmo Virtamo; Victoria K Cortessis; Manuela Gago-Dominguez; Malcolm C Pike; Mariana C Stern; Jian-Min Yuan; David J Hunter; Monica McGrath; Colin P Dinney; Bogdan Czerniak; Meng Chen; Hushan Yang; Sita H Vermeulen; Katja K Aben; J Alfred Witjes; Remco R Makkinje; Patrick Sulem; Soren Besenbacher; Kari Stefansson; Elio Riboli; Paul Brennan; Salvatore Panico; Carmen Navarro; Naomi E Allen; H Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Neil Caporaso; Maria Teresa Landi; Federico Canzian; Borje Ljungberg; Anne Tjonneland; Francoise Clavel-Chapelon; David T Bishop; Mark T W Teo; Margaret A Knowles; Simonetta Guarrera; Silvia Polidoro; Fulvio Ricceri; Carlotta Sacerdote; Alessandra Allione; Geraldine Cancel-Tassin; Silvia Selinski; Jan G Hengstler; Holger Dietrich; Tony Fletcher; Peter Rudnai; Eugen Gurzau; Kvetoslava Koppova; Sophia C E Bolick; Ashley Godfrey; Zongli Xu; José I Sanz-Velez; María D García-Prats; Manuel Sanchez; Gabriel Valdivia; Stefano Porru; Simone Benhamou; Robert N Hoover; Joseph F Fraumeni; Debra T Silverman; Stephen J Chanock
Journal:  Nat Genet       Date:  2010-10-24       Impact factor: 38.330

View more
  28 in total

1.  Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium.

Authors:  Todd M Gibson; Karin E Smedby; Christine F Skibola; David W Hein; Susan L Slager; Silvia de Sanjosé; Claire M Vajdic; Yawei Zhang; Brian C-H Chiu; Sophia S Wang; Henrik Hjalgrim; Alexandra Nieters; Paige M Bracci; Anne Kricker; Tongzhang Zheng; Carol Kolar; James R Cerhan; Hatef Darabi; Nikolaus Becker; Lucia Conde; Theodore R Holford; Dennis D Weisenburger; Anneclaire J De Roos; Katja Butterbach; Jacques Riby; Wendy Cozen; Yolanda Benavente; Casey Palmers; Elizabeth A Holly; Joshua N Sampson; Nathaniel Rothman; Bruce K Armstrong; Lindsay M Morton
Journal:  Cancer Causes Control       Date:  2012-11-18       Impact factor: 2.506

Review 2.  Current status of genome-wide association studies in cancer.

Authors:  Charles C Chung; Stephen J Chanock
Journal:  Hum Genet       Date:  2011-06-16       Impact factor: 4.132

3.  Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.

Authors:  Supharat Suvichapanich; Sukanya Wattanapokayakit; Taisei Mushiroda; Hideki Yanai; Charoen Chuchottawon; Tassawan Kantima; Supalert Nedsuwan; Wimon Suwankesawong; Cholticha Sonsupap; Roongkarn Pannarunothai; Sukanya Tumpattanakul; Warawut Bamrungram; Achara Chaiwong; Surakameth Mahasirimongkol; Sasithorn Mameechai; Weerapat Panthong; Nantawan Klungtes; Amara Munsoo; Udomrat Chauychana; Molrudee Maneerat; Koya Fukunaga; Yosuke Omae; Katsushi Tokunaga
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Red meat intake, NAT2, and risk of colorectal cancer: a pooled analysis of 11 studies.

Authors:  Ashwin N Ananthakrishnan; Mengmeng Du; Sonja I Berndt; Hermann Brenner; Bette J Caan; Graham Casey; Jenny Chang-Claude; David Duggan; Charles S Fuchs; Steven Gallinger; Edward L Giovannucci; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Lifang Hou; Li Hsu; Mark A Jenkins; Peter Kraft; Jing Ma; Hongmei Nan; Polly A Newcomb; Shuji Ogino; John D Potter; Daniela Seminara; Martha L Slattery; Mark Thornquist; Emily White; Kana Wu; Ulrike Peters; Andrew T Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-23       Impact factor: 4.254

5.  Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms.

Authors:  Jonine D Figueroa; Stella Koutros; Joanne S Colt; Manolis Kogevinas; Montserrat Garcia-Closas; Francisco X Real; Melissa C Friesen; Dalsu Baris; Patricia Stewart; Molly Schwenn; Alison Johnson; Margaret R Karagas; Karla R Armenti; Lee E Moore; Alan Schned; Petra Lenz; Ludmila Prokunina-Olsson; A Rouf Banday; Ashley Paquin; Kris Ylaya; Joon-Yong Chung; Stephen M Hewitt; Michael L Nickerson; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Núria Malats; Joseph F Fraumeni; Stephen J Chanock; Nilanjan Chatterjee; Nathaniel Rothman; Debra T Silverman
Journal:  J Natl Cancer Inst       Date:  2015-09-14       Impact factor: 13.506

6.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

Review 7.  The genetics of cancer risk.

Authors:  Mark M Pomerantz; Matthew L Freedman
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

8.  Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.

Authors:  Montserrat Garcia-Closas; Nathaniel Rothman; Jonine D Figueroa; Ludmila Prokunina-Olsson; Summer S Han; Dalsu Baris; Eric J Jacobs; Nuria Malats; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Sapna Sharma; Yi-Ping Fu; Manolis Kogevinas; Zhaoming Wang; Wei Tang; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Susan M Gapstur; Michael Thun; William Ryan Diver; Stephanie J Weinstein; Jarmo Virtamo; David J Hunter; Neil Caporaso; Maria Teresa Landi; Amy Hutchinson; Laurie Burdett; Kevin B Jacobs; Meredith Yeager; Joseph F Fraumeni; Stephen J Chanock; Debra T Silverman; Nilanjan Chatterjee
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

Review 9.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

10.  Genome-wide interaction study of smoking and bladder cancer risk.

Authors:  Jonine D Figueroa; Summer S Han; Montserrat Garcia-Closas; Dalsu Baris; Eric J Jacobs; Manolis Kogevinas; Molly Schwenn; Nuria Malats; Alison Johnson; Mark P Purdue; Neil Caporaso; Maria Teresa Landi; Ludmila Prokunina-Olsson; Zhaoming Wang; Amy Hutchinson; Laurie Burdette; William Wheeler; Paolo Vineis; Afshan Siddiq; Victoria K Cortessis; Charles Kooperberg; Olivier Cussenot; Simone Benhamou; Jennifer Prescott; Stefano Porru; H Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Börje Ljungberg; Françoise Clavel-Chapelon; Elisabete Weiderpass; Vittorio Krogh; Miren Dorronsoro; Ruth Travis; Anne Tjønneland; Paul Brenan; Jenny Chang-Claude; Elio Riboli; David Conti; Manuela Gago-Dominguez; Mariana C Stern; Malcolm C Pike; David Van Den Berg; Jian-Min Yuan; Chancellor Hohensee; Rebecca Rodabough; Geraldine Cancel-Tassin; Morgan Roupret; Eva Comperat; Constance Chen; Immaculata De Vivo; Edward Giovannucci; David J Hunter; Peter Kraft; Sara Lindstrom; Angela Carta; Sofia Pavanello; Cecilia Arici; Giuseppe Mastrangelo; Margaret R Karagas; Alan Schned; Karla R Armenti; G M Monawar Hosain; Chris A Haiman; Joseph F Fraumeni; Stephen J Chanock; Nilanjan Chatterjee; Nathaniel Rothman; Debra T Silverman
Journal:  Carcinogenesis       Date:  2014-03-24       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.